Archives mei 2023

More vaccinated deaths than unvaccinated deaths from covid (US)

58% of covid US deaths now in the vaccinated

Kaiser Family Foundation vice president Cynthia Cox

https://www.cdc.gov/vaccines/covid-19/effectiveness-research/protocols.html

https://covid.cdc.gov/covid-data-tracker/#rates-by-vaccine-status

https://www.cdc.gov/coronavirus/2019-ncov/vaccines/effectiveness/monitoring.html

https://data.cdc.gov/Public-Health-Surveillance/Rates-of-COVID-19-Cases-or-Deaths-by-Age-Group-and/d6p8-wqjm

https://www.washingtonpost.com/politics/2022/11/23/vaccinated-people-now-make-up-majority-covid-deaths/

58% of coronavirus deaths in August were people who were vaccinated or boosted

(people who had completed at least their primary series of vaccines)

Therefore 42% coronavirus deaths in August were people who were unvaccinated

First time there were more deaths covid deaths in the vaccinated versus the unvaccinated

https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-people-booster-percent-pop5

In September 2021
Vaccinated people, 23% of coronavirus fatalities

In January and February 2022

Vaccinated people, 42% of coronavirus fatalities

We can no longer say this is a pandemic of the unvaccinated

(who conducted the analysis on behalf of the Post)

https://www.cdc.gov/mmwr/volumes/71/wr/mm7144a3.htm?s_cid=mm7144a3_w

Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥12 Years — United States, August 31–October 23, 2022

On August 31, 2022

FDA authorized bivalent, Pfizer-BioNTech and Moderna

mRNA encoding the spike protein from original strain of SARS-CoV-2,

and from Omicron BA.4 and BA.5

Advisory Committee on Immunization Practices (ACIP) recommended,

all persons ≥12 years receive an age-appropriate bivalent mRNA booster dose

v-safe

a voluntary smartphone-based U.S. safety surveillance system,

established by CDC to monitor adverse events after COVID-19 vaccination

As of 3rd October, 10 million users

BREAKING NEWS: ICAN Obtains CDC V-Safe Data

Vaccine Adverse Event Reporting System (VAERS)

Total data, August 31–October 23, 2022

14.4 million received a bivalent Pfizer-BioNTech

8.2 million adults (≥18 years) a bivalent Moderna booster dose

v-safe, among the 211,959 registrants (aged ≥12 years)

August 31–October 23, 2022

Reported in the week after vaccination

Injection site reactions, 60.8%

Systemic reactions, 54.8%

Fewer than 1% of v-safe registrants reported receiving medical care

Vaccine Adverse Event Reporting System (VAERS)

5,542 reports of adverse events after bivalent booster vaccination (≥12 years)

95.5% of reports were nonserious

4.5% were serious events

Health care providers and patients can be reassured that adverse events reported after a bivalent booster dose are consistent with those reported after monovalent doses.

Relative risk

Absolute risk not given

Health impacts after COVID-19 vaccination are less frequent and less severe than those associated with COVID-19 illness (2).

Relative risk

Absolute risk not given

This is their Reference 2

Block JP, Boehmer TK, Forrest CB, et al. Cardiac complications after SARS-CoV-2 infection and mRNA COVID-19 vaccination—PCORnet, United States, January 2021–January 2022. MMWR Morb Mortal Wkly Rep 2022;71:517–23. https://doi.org/10.15585/mmwr.mm7114e1 PMID:35389977

myocarditis; myocarditis or pericarditis; and myocarditis, pericarditis, or MIS,

within 7-day or 21-day risk windows after the index date

Comparisons between after vaccine and after infection

Relative risk

Absolute risk not given

Review of v-safe Data

During August 31–October 23, 2022

211,959 v-safe registrants had a bivalent booster

1,464 (0.7%) were aged 12–17 years

68,592 (32.4%) were aged 18–49 years

59,209 (27.9%) were aged 50–64 years

82.694 (39.0%) were aged ≥65 years

Fourth dose

96,241; 45.4%

Fifth dose

106,423; 50.2%

In the week after receipt of the bivalent booster dose

Local injection site reactions

49.7% among aged ≥65

72.9% among aged 18–49

Systemic reactions

43.5% among aged ≥65

67.9% among aged 18–49

Systemic symptoms

Fatigue (30.0%–53.1%)

Headache (19.7%–42.8%)

Myalgia (20.3%–41.3%)

Fever (10.2%–26.3%)

Reported inability to complete normal daily activities

10.6% among aged ≥65 years

19.8% among aged 18–49 years

Receipt of medical care

Reported by 0.8% of registrants